Mega menu

Home
Product regulation
Product regulation

Understand your obligations and access industry Guidance and other information about the products we regulate.
Safety and shortages
Safety and shortages

Access information about product recalls, shortages and other alerts, and learn how we manage safety.
Resources and guidance
Resources and guidance

Get information to help you understand our work, regulations and industry obligations.
Business services
Business services

Access our systems to submit applications, manage forms, make payments and communicate securely.

AstraZeneca Pty Ltd

Regulatory activities for this sponsor.

- LinkedIn
- (Twitter)
- Facebook
- Email

Loading...

Type

ARTG (111)
Cancellation by sponsor (70)
Prescription medicine registration (60)
Australian public assessment report (AusPar) (48)
Designation or determination (24)
Prescription medicine decision summary (12)
Prescription medicine evaluation (10)
Section 14, TGO91 consent (1)

Date

2026 (15)
2025 (32)
2024 (28)
2023 (30)
2022 (45)
2021 (25)
2020 (16)
2019 (20)
2018 (19)
2017 (14)
2016 (11)
2015 (14)
2014 (13)
2013 (6)
2012 (3)
2011 (5)
2010 (4)
2008 (3)
2006 (5)
2004 (2)
2003 (5)
2002 (2)
2001 (2)
1997 (2)
1996 (3)
1991 (12)

Search

Sponsor content

336 result(s) found, displaying 31 to 40

ASTRAZENECA GOSERELIN goserelin 3.6mg (as acetate) implant syringe Cancelled under Section 30(1)(c) of the Act

3 June 2025

Cancellation by sponsor

Requested by AstraZeneca Pty Ltd
ASTRAZENECA GOSERELIN goserelin 10.8mg (as acetate) implant syringe Cancelled under Section 30(1)(c) of the Act

3 June 2025

Cancellation by sponsor

Requested by AstraZeneca Pty Ltd
WAINUA AstraZeneca Pty Ltd

Jun-2025

Prescription medicine evaluation

Active ingredient: eplontersen sodium.
FASLODEX fulvestrant 250mg/5mL solution for injection pre-filled syringe Cancelled under Section 30(1)(c) of the Act

28 May 2025

Cancellation by sponsor

Requested by AstraZeneca Pty Ltd
AstraZeneca Pty Ltd - Medicine administration kit, percutaneous, medicated, single-use Cancelled under Section 41GL(d) of the Act

28 May 2025

Cancellation by sponsor

Requested by AstraZeneca Pty Ltd
ENHERTU (AstraZeneca Pty Ltd)

27 May 2025

Prescription medicine registration

Active ingredients: trastuzumab deruxtecan.
KAVIGALE, (AstraZeneca Pty Ltd)

20 May 2025

Prescription medicine registration

Active ingredients: sipavibart.
DATROWAY (AstraZeneca Pty Ltd)

15 May 2025

Prescription medicine registration

Active ingredients: datopotamab deruxtecan.
Notice for camizestrant (AstraZeneca Pty Ltd)

5 May 2025

Designation or determination

Priority review
IMFINZI (AstraZeneca Pty Ltd)

15 April 2025

Prescription medicine registration

Active ingredients: durvalumab.

Pages

First page
Previous page
Page 1
Page 2
Page 3
Current page 4
Page 5
Page 6
Page 7
Page 8
Page 9
…
Next page
Last page

Using our website

Accessibility
Privacy
Security
Disclaimer
Copyright
Freedom of information
Acronyms and glossary terms

Quick links

Search our databases
Report a problem or side effect
TGA Business Services
Special Access Scheme
Authorised Prescriber
Office of Drug Control
State and territory contacts

Connect with us

Email subscriptions
Contact us
Facebook
(formerly Twitter)
Youtube
Instagram
LinkedIn

Help us improve

We are always looking for ways to improve our website.

Provide feedback

The Department of Health, Disability and Ageing acknowledges First Nations peoples as the Traditional Owners of Country throughout Australia, and their continuing connection to land, sea and community. We pay our respects to them and their cultures, and to all Elders both past and present.